Phase 2 Study of Nivolumab in Patients With Primary Myelofibrosis, Post-Essential Thrombocythemia Myelofibrosis, or Post-Polycythemia Vera Myelofibrosis
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 08 Nov 2017
At a glance
- Drugs Nivolumab (Primary)
- Indications Myeloproliferative disorders
- Focus Therapeutic Use
- 31 Oct 2017 Status changed from recruiting to active, no longer recruiting.
- 14 May 2015 Planned primary completion date changed from 1 Aug 2020 to 1 May 2020 as per ClinicalTrials.gov record.
- 14 May 2015 Status changed from not yet recruiting to recruiting as per ClinicalTrials.gov record.